Document Detail


Monitoring birth outcomes in the Sumatriptan Pregnancy Registry.
MedLine Citation:
PMID:  10838359     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Background: Health professionals often need to make medical management decisions by weighing potential risk versus benefit. Because 50% of pregnancies in the United States are unplanned, the likelihood for unintentional first-trimester exposure to medications is high and increases when women of childbearing potential (ages 15-44) are taking medications used to treat chronic or recurrent conditions, such as migraine. Prospective collection of pregnancy exposure and outcome data is one method for providing data to the medical community as a tool for making risk assessments.Methods: The Sumatriptan Pregnancy Registry is an international, exposure-registration and follow-up study to prospectively collect prenatal sumatriptan exposure and outcome data. An advisory committee reviews data and assists in disseminating information. Committee members include independent scientists with expertise in obstetrics, pediatrics, neurology, internal medicine, epidemiology, clinical genetics, and teratology.Results: As of April 30, 1997, 181 outcomes were prospectively reported from pregnancies involving use of sumatriptan. Of the 171 outcomes where earliest exposure was in the first trimester there were 143 infants without birth defects, 4 live infants with birth defects, 1 stillbirth with birth defects [12 spontaneous pregnancy losses, 2 stillbirths, and 9 induced abortions without birth defects]. The proportion of outcomes involving birth defects, 5/148, 3.4% (95% CI 1.3%, 8.1%), does not differ from the expected proportion in the general population.Conclusions: To date, no pattern has emerged in either the prospectively or retrospectively reported defects. Registry data are disseminated to interested health care providers who are then in a more informed position when making medical management decisions. However, more data are needed before definitive conclusions can be drawn about the safety of sumatriptan use in pregnancy.
Authors:
Eldridge; Ephross
Related Documents :
23899239 - Current recommendations for multiple sclerosis treatment in pregnancy and puerperium.
23097739 - Virilisation during pregnancy in a patient with metastatic colorectal cancer.
20132339 - Triptan exposure during pregnancy and the risk of major congenital malformations and ad...
2351529 - Heavy lifting during pregnancy--a hazard to the fetus? a prospective study.
24943879 - Systemic immunosuppression by methylprednisolone and pregnancy rates in goats undergoin...
19279389 - The impact of first-trimester serum free beta-human chorionic gonadotropin and pregnanc...
6544839 - Otolaryngological manpower in canada--1983.
22523879 - Management options and prognosis of pancreatic adenocarcinoma at 16 weeks' gestation: a...
6691389 - Etiologic factors and subsequent reproductive performance in 195 couples with a prior h...
Publication Detail:
Type:  JOURNAL ARTICLE    
Journal Detail:
Title:  Primary care update for Ob/Gyns     Volume:  5     ISSN:  -     ISO Abbreviation:  Prim. Care Update Ob Gyns     Publication Date:  1998 Jul 
Date Detail:
Created Date:  2000-06-05     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9431228     Medline TA:  Prim Care Update Ob Gyns     Country:  -    
Other Details:
Languages:  ENG     Pagination:  190     Citation Subset:  -    
Affiliation:
Glaxo Wellcome, Research Triangle Park, North Carolina, USA
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Screening for gestational diabetes mellitus in adolescent Hispanics.
Next Document:  Monitoring pregnancy outcomes following prenatal drug exposure through prospective pregnancy registr...